Get Started

VRDN

NASD Viridian Therapeutics, Inc.
Nov 5, 2026 · 10:29 AM ET DELAYED Market Open

$29.22 ↑ +0.16 (+0.55%) Trading Up from the previous close of $29.06, $0.40 below the day’s high of $29.61

YTD change
-6.12%
vs 20-day SMA
+32.02%
vs 200-day SMA
+34.89%

Price ranges

Previous day
$25.07 $29.74
open $28.99 close $29.06
+$0.07 (+0.22%)
Today
$28.48 $29.61
open $29.58 now $29.22
-$0.36 (-1.23%)
Past week
$23.97 $29.74
from $24.27 now $29.22
+$4.95 (+20.37%)
Past month
$17.59 $29.74
from $18.28 now $29.22
+$10.94 (+59.82%)
This year
$13.18 $34.29
from $31.12 now $29.22
-$1.91 (-6.12%)

Price & Performance

+10.30 (+54.96%) / 6M

$14.66$19.82$24.97$30.12May 5Aug 5Nov 4

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Very Good
  • The stock is 25.1% away from all-time highs of $39.00
  • VRDN is down 6% since the beginning of the year
  • VRDN is up 20% over the past 12 months
  • VRDN is up 60% over the past 1 month
  • 16% of all VRDN investors are betting against VRDN

VRDN reads very good: price sits above both the 20- and 200-day averages, the 12-month move is +19.0%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-0.81
Earnings momentum -26.2% Quarterly EPS growth
Quarterly change -26.2%

Valuation

P/E ratio N/A
Enterprise value $2.5B
Beta 1.65

Balance sheet & scale

IncomeN/A
Revenue$26.3M
Cash$956.5M
Debt$243.3K
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Professional, Scientific, and Technical Services
Industry Group Scientific Research and Development Services
Market cap $3.3B

Viridian Therapeutics, Inc. is a biopharmaceutical company that develops medicines for autoimmune and rare diseases. It uses antibody discovery and protein engineering to create new therapies. The company is advancing late-stage IGF-1R therapies for thyroid eye disease (TED) and developing a potential TSHR-targeted treatment for TED and Graves’ disease. In addition, it is developing FcRn inhibitors, including VRDN-006 and VRDN-008, for multiple autoimmune diseases. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Competitor comparison

TickerCompany PriceChange
AMGN Amgen Inc. $478.48 +3.73%
MRNA Moderna, Inc. $258.38 +13.11%
RVMD Revolution Medicines, Inc. $199.70 +2.82%
ROIV Roivant Sciences Ltd. $38.23 +6.08%
BNTX BioNTech SE Sponsored ADR $90.70 +4.35%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.